Psilocybin for Veterans with PTSD: Research and Advocacy

Psilocybin & PTSD

47% response at 12 weeks

In the first psilocybin pilot designed exclusively for U.S. military veterans, 47% still met response criteria at 12 weeks, in patients who had failed multiple prior treatments.

Ellis et al., Journal of Affective Disorders, 2025

85%

of surveyed veterans who used psychedelics reported benefit

9 VA facilities

enrolled in the VA's formal psychedelic research program

58 veterans

showed improvements in real-world retreat-based psilocybin data

Ellis et al., Journal of Affective Disorders, 2025

View as image ↗

In 2025, Ellis and colleagues published results from the first clinical psilocybin pilot designed exclusively for U.S. military veterans. The fifteen participants all had severe treatment-resistant depression, meaning they had not responded adequately to prior antidepressant treatments. Sixty percent responded to psilocybin by week three. At week twelve, 47% still met response criteria.^[1]

Psilocybin for veterans with PTSD now sits at the intersection of an accelerating research program and a well-organized advocacy movement. Veterans seeking treatment for the overlap between PTSD and depression are among the hardest patient populations to treat, and the evidence from 2025 suggests psilocybin deserves serious clinical investigation in that population. This article covers what the data currently show, what the VA is doing institutionally, and which organizations are pushing for expanded access. For the full landscape of psilocybin PTSD clinical trials, see Psilocybin for PTSD: What the Clinical Trials Show.

The Only Published Psilocybin Pilot Designed for U.S. Veterans: What Ellis 2025 Found

Ellis and colleagues built their study around a population that rarely appears in psilocybin research: U.S. military veterans with severe, treatment-resistant depression. Treatment-resistant here means patients who had not responded adequately to antidepressant treatment, defined as failure to respond to at least two adequate prior medication trials. These were patients where standard options had already come up short.

All fifteen participants received a single supervised psilocybin session, with structured preparation sessions before and integration sessions after. Psychological support was provided throughout.

The week-three results were notable. Sixty percent of participants met the threshold for treatment response, meaning their depression symptom scores dropped by a clinically meaningful amount. Fifty-three percent were in full remission. At week twelve, 47% still met response criteria and 40% remained in remission.^[1]

The finding that mattered most for the veteran-specific context: participants who also had PTSD alongside their depression did not respond significantly differently from those without PTSD. In a population where the two conditions frequently overlap, psilocybin's antidepressant effect did not appear to be blocked or meaningfully reduced by the presence of PTSD.^[1]

The study was small and uncontrolled, and those limitations are real. Open-label pilots without placebo comparators cannot isolate the drug effect from expectation, the therapeutic relationship, or natural recovery. But as the first published psilocybin study focused exclusively on the veteran population, it provides a starting point that previously did not exist.

The only veteran-exclusive psilocybin pilot

Ellis et al. (2025) · Journal of Affective Disorders

Population

15 U.S. military veterans with severe, treatment-resistant depression (failure of at least two adequate prior medication trials); a subset also had comorbid PTSD

Intervention

A single supervised psilocybin session with structured preparation and integration and psychological support throughout

Comparator

None — open-label, single-arm pilot with no placebo

Finding

At week three, 60% met response criteria and 53% were in full remission. At week twelve, 47% still met response criteria and 40% remained in remission. Participants with comorbid PTSD did not respond significantly differently from those without.

preliminary Small (n=15), open-label, and uncontrolled — the effect cannot be separated from expectation, the therapeutic relationship, or natural recovery. It establishes feasibility in veterans, not efficacy.

Ellis et al., Journal of Affective Disorders, 2025

58 Veterans Attended Retreats in Jamaica and Peru. Here's What Happened.

Not all veteran psychedelic research happens inside clinical trials. Calnan and colleagues, including Robin Carhart-Harris from UC San Francisco, documented outcomes from 58 military veterans who attended psychedelic retreats through the Heroic Hearts Project, a nonprofit that funds retreat experiences for veterans with treatment-resistant conditions.^[2]

Thirty-three veterans attended psilocybin-assisted retreats in Jamaica. The other 25 attended ayahuasca retreats in Peru. Researchers assessed participants before the retreat and at follow-up for PTSD severity, depression, anxiety, post-concussion symptoms, and reintegration into civilian life.

Both groups improved across most measures. The two substances showed different patterns of strength. Psilocybin produced larger effects for depression, anxiety, post-concussion symptoms, and social reintegration. Ayahuasca produced larger effects for PTSD symptom reduction specifically.^[2]

The limitations here are significant, and the authors are clear about them. The study was observational, not randomized. Veterans self-selected into retreats, which means participants who sought out this experience may have been more motivated or more likely to respond. There was no control group. The retreats included peer support, structured intention-setting, multi-day community, and professional integration support, all of which could independently contribute to outcomes. The drug effect cannot be isolated from the retreat experience.

What the Calnan study provides, despite those limits, is documented real-world data from a veteran population using psilocybin outside controlled settings. That population exists and is growing. The data give researchers a field-level picture that lab-based trials, which often exclude the most complex cases, do not capture.

51% of Veterans Are Already Using Psychedelics. 85% Say It Helps.

The research push did not come from nowhere. Davis and colleagues surveyed 426 U.S. military veterans about their psychedelic use in a cross-sectional study published in the Journal of Psychoactive Drugs.^[3]

Fifty-one percent of respondents reported having used psychedelics at some point. Among those who had, 70% said they used them for healing or therapeutic purposes. Forty-eight percent reported using them for spiritual growth. Eighty-five percent reported the experience was beneficial.^[3]

Psilocybin specifically showed fewer adverse outcomes than other psychedelics in the dataset, consistent with what supervised clinical trials have found.

The finding that carries the most policy weight: veterans who had used psychedelics said they would be more likely to return to VA care if psilocybin-assisted therapy was offered, not less. In a system that has historically been seen as punitive toward veterans with unconventional treatment histories, this result suggests psilocybin therapy could draw veterans back into the VA system rather than push them further away.^[3]

The survey has real limitations. It was retrospective and self-selected: veterans who chose to respond likely skew toward those with positive experiences. Veterans who had difficult or harmful experiences may not have responded, which means the 85% benefit figure should be interpreted with that bias in mind. But the directional signal, across 426 respondents, is consistent enough to be meaningful.

The VA's Formal Response: 9 Facilities and a 2024 Implementation Charter

As recently as 2023, Walter Reed researchers Wolfgang and Hoge published a review noting that zero clinical trials had examined psilocybin for PTSD in any population, military or civilian. They mapped the clinical, legal, and implementation barriers that would need to be resolved before the VA could meaningfully engage with psychedelic-assisted therapy.^[5]

The institutional response in the following two years was unusually fast. In April 2024, the Department of Veterans Affairs formally chartered an Integrated Project Team specifically to plan the implementation of psychedelic-assisted therapy across the VA system. By 2025, that effort involved nine VA facilities in multi-year research programs. Wolfgang and colleagues reported the structure in the American Journal of Psychiatry: four workstreams organized around research design, clinical implementation, workforce training, and program evaluation.^[4]

This is an institutional commitment, not just a funding announcement. The four-workstream structure suggests the VA is thinking about psilocybin not only as a research question but as a potential clinical program that would need to be staffed, standardized, and evaluated at scale.

Veterans who want access to psilocybin therapy through VA channels cannot yet get it. The April 2024 charter and the nine participating facilities are research infrastructure, not a treatment pathway. But the VA moving from zero trials and no institutional plan in 2023 to a formal implementation team across nine facilities in 2025 represents a meaningful shift in where the institution stands.

The First Clinical Trial Built Specifically for Psilocybin and PTSD

The Ellis pilot enrolled veterans with treatment-resistant depression, some of whom also had PTSD. The McGowan study went further: it was the first published clinical trial designed specifically to examine psilocybin in patients with a primary diagnosis of PTSD.^[6]

The trial administered 25 mg of COMP360, a synthesized psilocybin formulation developed by COMPASS Pathways. It ran across sites in the UK and United States between June 2022 and February 2024. The authorship is worth noting: Rachel Yehuda, one of the world's most cited PTSD researchers, and Guy Goodwin, the principal investigator on COMP360's depression trials, were both involved. That combination reflects psilocybin being taken seriously as a primary PTSD treatment, not just a depression treatment where PTSD might appear as a secondary measure.^[6]

The primary aim of the trial was safety and tolerability, not efficacy. The researchers found psilocybin safe and tolerable in PTSD patients. That finding addresses a question that had to be answered before efficacy trials could proceed: can psilocybin be administered to someone with active PTSD without unacceptable harm, given the nature of the psychological experience it produces?

The McGowan answer was yes: with appropriate support structures, a supervised psilocybin session appeared to be tolerable for PTSD patients. That safety basis opens the path for larger randomized efficacy trials, which are now being designed and run.

Veterans Aren't Waiting: The Ibogaine Data and the Urgency Behind the Push

In 2024, a different psychedelic made headlines for what it did in veterans. Cherian and colleagues from the Williams lab at Stanford published results in Nature Medicine from a pilot study of 30 special operations veterans who received ibogaine treatment combined with magnesium at a clinic in Mexico. These were veterans with traumatic brain injury, PTSD, and suicidal ideation who had exhausted available treatment options and traveled abroad for access.^[8]

One month after treatment, the veterans showed dramatic improvements across PTSD severity, depression, anxiety, and functional disability. Baseline scores in this cohort were severe; the improvements were large across every measure. Nature Medicine, one of the most selective journals in medicine, published the findings.^[8]

Ibogaine carries serious cardiac risks, specifically the risk of dangerous heart rhythm disturbances, that make it unsuitable for broad clinical use. But the ibogaine data raised the stakes for psilocybin research in a specific way. If veterans with TBI, severe PTSD, and suicidal ideation showed that magnitude of improvement from a structurally different psychedelic administered without hospital safety infrastructure, the question of what psilocybin might produce in a properly supervised clinical setting became harder to ignore.

First responders with occupational trauma face a comparable treatment gap. That population is covered in Can Psilocybin Help First Responders with PTSD?

What the Legislative Push Has Achieved, and Where the Gap Remains

Siegel and colleagues analyzed the U.S. psychedelic legislative landscape in a JAMA Psychiatry review, noting that veteran advocacy had become one of the most visible political drivers of psychedelic reform.^[9]

The legislative picture they documented included Oregon's Measure 109, which created a licensed psilocybin services framework; Colorado's Proposition 122; state-level decriminalization in a growing number of cities; and federal proposals. The Psychedelic Action in Healing Caucus (PATH Caucus) brought together members of Congress around veteran access to psychedelic therapies, with bipartisan support in both chambers.^[9]

What the advocacy and legislative push has accomplished: increased VA research investment, the April 2024 implementation charter, political pressure that moved the VA faster than it might otherwise have moved, and growing public awareness of the treatment gap. Advocacy organizations including Veterans Exploring Treatment Solutions (VETS) and the Heroic Hearts Project have also generated the real-world data that researchers then analyze, creating a feedback loop between advocacy and evidence.

What the push has not accomplished: any change to psilocybin's Schedule I status at the federal level. No clinical pathway for VA facilities to administer psilocybin outside research protocols. No reimbursement pathway for private psilocybin therapy. The options available to a veteran who wants psilocybin therapy today are: enroll in a clinical trial, travel to a country where it is not prohibited, or access it through state-level frameworks in Oregon or Colorado, outside any clinical or insurance structure.

Legal & safety status

Moderate

Psilocybin remains federally illegal, and self-directed use carries real risk

Concern

Psilocybin is a Schedule I controlled substance under U.S. federal law, so no VA facility can provide it outside an approved trial. Veterans who obtain it independently — at unregulated retreats or abroad — do so without medical screening, supervision, or integration support, and psilocybin can precipitate acute psychological distress in people with active PTSD or a personal or family history of psychotic disorders. The ibogaine data referenced above involved a different drug with serious cardiac risks and is not a template for at-home psilocybin use.

What the research says

The controlled trials showing safety did so with careful participant screening, a supervised session, and structured preparation and integration — the conditions under which the favorable safety profile was observed.

Particularly relevant for: Veterans with active PTSD, suicidal ideation, or a personal or family history of psychosis or bipolar disorder should be especially cautious.

What to do

This article is educational and not medical advice. Veterans considering psilocybin should talk with a qualified clinician and look first to registered clinical trials rather than unsupervised access.

Schedule I status per U.S. federal law; safety framing per McGowan et al., 2025 and Ellis et al., 2025

When Lykos Therapeutics' MDMA application was rejected by the FDA in 2024, the urgency behind psilocybin research intensified further. That context is covered in After Lykos: What Psilocybin Means for Psychedelic PTSD Treatment.

What the Evidence Can and Cannot Support Right Now

Varker and colleagues published a systematic review of the evidence for MDMA, ketamine, LSD, and psilocybin in PTSD in 2021. Their conclusion was clear: MDMA had the strongest PTSD-specific evidence. Psilocybin evidence for PTSD was limited, despite the mechanistic case being compelling.^[7]

Four years later, the picture has shifted at the edges but the core conclusion still holds.

Evidence quality — psilocybin for veteran PTSD

1. Case Reports & Observational Seriescompleted

   58 veterans in retreat-based settings improved across PTSD, depression, anxiety, and reintegration (Calnan 2025); survey of 426 veterans found 85% reported benefit from psychedelic use (Davis 2025)

2. Small Human Trialscurrent

   A 15-veteran open-label pilot showed 47% response at 12 weeks for treatment-resistant depression (Ellis 2025); a dedicated PTSD trial found 25 mg psilocybin safe and tolerable (McGowan 2025)

3. Large Randomized Trialsmissing

   No completed RCT has tested psilocybin with PTSD symptom reduction as the primary outcome. VA-funded efficacy trials across nine facilities are now underway (Wolfgang 2025)

4. Meta-Analyses & Systematic Reviewsmissing

   A 2021 systematic review found psilocybin PTSD evidence limited compared with MDMA (Varker 2021); too few controlled psilocybin trials exist to synthesize

For PTSD specifically, the evidence has climbed to small, mostly uncontrolled human trials — enough to establish safety and generate promising signals, but not efficacy. The decisive rung, a properly powered randomized controlled trial with PTSD reduction as the primary endpoint, has not yet been reported.

Ellis 2025; McGowan 2025; Calnan 2025; Davis 2025; Varker 2021; Wolfgang 2025

What the evidence as of 2025 does support: a single psilocybin session produced meaningful antidepressant response at 12 weeks in U.S. military veterans with severe treatment-resistant depression, with comorbid PTSD not diminishing that effect (Ellis 2025). Psilocybin is safe and tolerable in PTSD patients, establishing the foundation for efficacy trials (McGowan 2025). Veterans in real-world retreat settings show improvements across PTSD, depression, and reintegration following psilocybin (Calnan 2025). Most veterans who have already used psychedelics report benefit and say they would be more likely to engage with VA care if psilocybin was offered (Davis 2025).

What the evidence cannot yet support: a firm claim that psilocybin treats PTSD in veterans. The mechanistic case is strong, the early signals are consistent, and the VA has now funded the trials designed to answer the question. What is missing is a properly powered randomized controlled trial with PTSD symptom reduction as the primary outcome.

For a side-by-side look at psilocybin and MDMA as PTSD treatment strategies, the comparison is covered in Psilocybin vs. MDMA for PTSD: Comparing Psychedelic Treatments.

The Bottom Line

Psilocybin research in veterans with PTSD has moved from theoretical to active clinical investigation. The first pilot designed exclusively for U.S. military veterans found 47% still responded at 12 weeks, and the first dedicated psilocybin PTSD safety trial reported favorable results in 2025. The VA formalized a psychedelic research program spanning nine facilities, and advocacy organizations are generating real-world outcome data alongside institutional research. What the field is still waiting for is a properly powered randomized controlled trial with PTSD symptom reduction as the primary outcome.

Frequently Asked Questions

Does the VA cover psilocybin therapy for veterans?

The VA does not currently offer or cover psilocybin therapy. Psilocybin remains a Schedule I controlled substance under federal law, which prohibits VA facilities from administering it outside of approved research settings. The VA chartered a formal Integrated Project Team for psychedelic research implementation in April 2024, now spanning nine VA facilities (Wolfgang et al., Am J Psychiatry, 2025), but that program involves clinical trials, not a standard treatment pathway. Veterans seeking psilocybin access currently need to enroll in a clinical trial or travel to a jurisdiction where it is legally available.

What organizations are advocating for psychedelic therapy for veterans?

Several organizations are actively working to expand veteran access to psychedelic therapy. The Heroic Hearts Project funds retreat experiences for combat veterans and has published observational outcome data from those programs (Calnan et al., 2025). Veterans Exploring Treatment Solutions (VETS) provides funding and support for veterans seeking psychedelic treatments. The PATH Caucus in Congress built bipartisan support for veteran psychedelic therapy legislation (Siegel et al., JAMA Psychiatry, 2023). The Disabled American Veterans and the American Legion have both engaged publicly with the issue.

Is psilocybin legal for veterans with PTSD?

Psilocybin is not federally legal in the U.S. for any indication, including PTSD. Veterans can legally participate in approved clinical trials without personally possessing the substance. In Oregon and Colorado, state-regulated therapeutic psilocybin frameworks now exist, though these operate outside any VA or insurance structure. Some veterans have traveled to Jamaica or the Netherlands, where psilocybin is not prohibited, to access retreat-based programs. Fifty-eight veterans documented in the Calnan 2025 study attended retreats in Jamaica and Peru through this kind of self-directed access.

What does the research say about psilocybin for veteran PTSD?

The research as of 2025 is promising but early. The only published pilot exclusively in U.S. military veterans found 47% responded at 12 weeks in a severely treatment-resistant population, with comorbid PTSD not meaningfully reducing that response (Ellis et al., 2025). A dedicated psilocybin PTSD safety trial found the treatment safe and tolerable (McGowan et al., 2025). Observational data from 58 veterans in retreat settings showed meaningful improvements across PTSD, depression, and reintegration measures (Calnan et al., 2025). A 2021 systematic review concluded psilocybin PTSD evidence remained limited compared to MDMA, which had the strongest psychedelic PTSD evidence base at the time (Varker et al., 2021). No completed randomized controlled trial has yet tested psilocybin against PTSD symptoms as a primary outcome.

How many veterans have PTSD?

PTSD is substantially more common among military veterans than in the general population, with combat exposure being one of the strongest risk factors for its development. In a survey of 426 U.S. military veterans, Davis and colleagues found that many had turned to psychedelics specifically for trauma-related healing, reflecting the gap between what standard VA treatment provides and what veterans report needing (Davis et al., 2025). The VA describes PTSD as one of its highest-volume mental health conditions. Veterans who do not respond adequately to first-line treatments, which include prolonged exposure therapy and cognitive processing therapy, represent the population most directly relevant to psilocybin clinical trial eligibility.

Sources & References

1. 1RTHM-00923·Ellis, Sara et al. (2025). “Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study..” Journal of affective disorders.Study breakdown →PubMed →↩
2. 2RTHM-02063·Calnan, Megan et al. (2025). “Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings..” Brain and behavior.Study breakdown →PubMed →↩
3. 3RTHM-02073·Davis, Alan K et al. (2025). “The Epidemiology of Psychedelic Use Among United States Military Veterans..” Journal of psychoactive drugs.Study breakdown →PubMed →↩
4. 4RTHM-02210·Wolfgang, Aaron S et al. (2025). “Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration..” The American journal of psychiatry.Study breakdown →PubMed →↩
5. 5RTHM-01820·Wolfgang, Aaron S et al. (2023). “Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations..” Current psychiatry reports.Study breakdown →PubMed →↩
6. 6RTHM-00941·McGowan, Niall M et al. (2025). “Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
7. 7RTHM-01449·Varker, Tracey et al. (2021). “Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin..” Journal of psychoactive drugs.Study breakdown →PubMed →↩
8. 8RTHM-01873·Cherian, Kirsten N et al. (2024). “Magnesium-ibogaine therapy in veterans with traumatic brain injuries..” Nature medicine.Study breakdown →PubMed →↩
9. 9RTHM-01791·Siegel, Joshua S et al. (2023). “Psychedelic Drug Legislative Reform and Legalization in the US..” JAMA psychiatry.Study breakdown →PubMed →↩